Tesamorelin vs Sermorelin

**ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. ** The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.

Tesamorelin and Sermorelin are both synthetic growth hormone-releasing hormone (GHRH) analogues. Sermorelin is often used as a treatment for growth hormone deficiency in both children and adults. Sermorelin works by mimicking the action of the natural hormone, growth hormone-releasing hormone (GHRH), to increase the production of growth hormone in the body. This can have various benefits, including promoting growth in children, increasing muscle mass, reducing body fat, improving sleep, and enhancing overall well-being. Sermorelin is typically administered to individuals with growth hormone deficiencies or certain medical conditions.

Tesamorelin is used primarily to treat excess abdominal fat accumulation in people living with HIV/AIDS who have developed lipodystrophy. Lipodystrophy is a condition characterized by abnormal fat distribution in the body. Tesamorelin works by stimulating the pituitary gland to release growth hormone, which can help reduce visceral fat (fat stored in the abdominal area) in these individuals. It is administered through daily injections.

Both peptides are known for their ability to bring about changes in body composition, and both have been linked to improvements in heart health and cognitive function in mouse models. Despite their similarities, however, there are unique differences between these peptides. Understanding the subtleties that arise between these two very similar peptides is helping researchers to better understand physiologic pathways and develop better, more advanced therapeutics.

Tesamorelin vs Sermorelin | A Note on Growth Hormone

Researchers have shown interest in growth hormone (GH) therapy as an alternative approach to address body composition independently of the androgen-dependent gonadal axis. Studies have demonstrated that GH therapy can yield positive effects, including increased lean body mass, reduced adiposity, and improved serum lipid profiles. Despite these promising results, the use of GH therapy remains a subject of controversy and is subject to strict regulation. Potential side effects include joint stiffness, radiculopathy, edema, and a theoretically suggested but unproven increased risk of malignancy. The issue with direct GH supplementation is that it can easily lead to overdose. The body lacks a direct feedback mechanism for regulating GH levels and instead regulates the entire GH axis at the levels of synthesis and secretion. Given the benefits of GH, researchers began seeking alternative ways to stimulate GH release to avoid the potential problems associated with direct GH supplementation.

The result of these efforts was the development of a new class of peptides referred to as growth hormone secretagogues. Growth hormone secretagogue therapy has emerged as a promising substitute for GH therapy. These compounds exhibit numerous favorable effects similar to GH therapy but without the associated adverse side effects or regulatory issues. Growth hormone secretagogues stimulate the body's own release of GH. This stimulation occurs either through direct mimicry of growth hormone release hormone (GHRH) or interactions with ghrelin/growth hormone secretagogue receptors (GHS-R), distinct from the conventional hypothalamic-pituitary-somatotropic axis. This article focuses on the growth hormone-releasing hormone (GHRH) analogues Tesamorelin and Sermorelin.

Research indicates that GHS treatment can elevate serum GH and IGF-1 levels to levels comparable to those achieved with recombinant GH therapy, resulting in similar reductions in fat and increases in lean muscle mass. Remarkably, specific GHS can uniquely induce the natural pulsatile secretion of GH observed in vivo. This stands in contrast to exogenous GH therapy, which often leads to sustained supraphysiological levels of GH in the bloodstream[1]. As a result, the administration of GHS has the potential to offer many of the same advantages traditionally associated with GH therapy while carrying substantially lower risks.

Tesamorelin vs Sermorelin | Body Composition

Tesamorelin and Sermorelin are both growth hormone secretagogues and, as a result, produce changes in body composition that favor lean mass over fat mass. Research shows that GHRH analogues all produce increases in muscle mass, muscle strength, and bone mass. They also lead to a decrease in fat mass.

Sermorelin is the older peptide and has been tested more extensively. Research shows that Sermorelin is a moderate muscle building peptide and that its main benefits are in favoring leaner body composition as opposed to strict muscle building. Tesamorelin falls into a similar categorization, though it tends to favor the destruction of fat mass as opposed to the building of lean body mass. Though not mentioned here, CJC-1295 is probably the best GHRH analogue when it comes to muscle building. It is the extremely long half-life of CJC-1295 that makes it such an effective muscle builder. At a half-life of approximately a week, CJC-1295 remains in the bloodstream orders of magnitude longer than Sermorelin, which has a 30-minute half-life, and Tesamorelin, which has a 30-minute half-life[2]. Given Tesamorelin’s similar half-life compared to Sermorelin, it is approximately equally as likely to produce significant muscle growth.

Research shows that both of these peptides increase both basal and pulsatile GH activity. Interestingly, both of these peptides appear to extend the duration of peaks and raise baseline levels of GH without actually increasing levels of GH peaks[3]. In other words, Sermorelin and Tesamorelin increase how long GH peaks last but don’t change maximal levels of GH secretion. This is probably why these peptides have reduced off-target effects compared to other GHRH analogues and other GH secretagogues. Unlike the ghrelin analogues, which increase maximum GH peak levels but not the duration of the GH spike, GHRH analogues tend to increase the duration of the spike without increasing the peak. This is probably the reason that GHRH analogues and ghrelin analogues are synergistic. Together they raise both peak and duration, causing massive increases in overall GH signaling.

It is important to note that research has shown that even though Tesamorelin has a half-life of just 30 minutes, its effects on GH can last for up to two weeks following cessation of treatment[4]. In other words, it takes two weeks after stopping Tesamorelin for its effects on GH levels to stop. Similar data is not available for Sermorelin.

By increasing exposure to GH over time, both Tesamorelin vs Sermorelin lead to changes in bone density, muscle density, and fat mass that favor the former over the latter. They appear to do this without causing a significant change in appetite. This is another factor that sets the GHRH analogues apart from the ghrelin analogues. Research shows that Tesamorelin, specifically, increases overall muscle area while decreasing muscle fat content, giving direct evidence of a body composition change that favors lean body mass and muscle strength[5].

Research indicates that both Tesamorelin and Sermorelin are potent fat burners, leading to an approximately 20% reduction in adiposity (fat mass) over the course of six months[3], [6]. This translates into approximately 10 pounds of fat loss for the average male and makes these peptides approximately four times more effective than existing fat-loss options including medications, diets, and exercise.

Tesamorelin vs Sermorelin | IGF-1

GH hormone is known to stimulate increases in IGF-1 levels. Insulin-like Growth Factor-1 (IGF-1) is produced by the liver and other tissues in response to growth hormone (GH) stimulation and plays a crucial role in promoting cell growth, development, and regeneration throughout the body. IGF-1's primary functions include stimulating growth during childhood and adolescence, supporting tissue repair and muscle growth in adults, and regulating metabolism and cell function. It is also implicated in various physiological processes, including bone health, immune function, and tissue maintenance. Abnormal levels of IGF-1 can contribute to various health issues, such as growth disorders or an increased risk of certain diseases. As a result, IGF-1 is an essential hormone for overall growth, development, and health throughout life.

Despite its benefits, IGF-1 has also been connected to several potential problems. Elevated levels of IGF-1 have been associated with an increased risk of certain cancers, including breast, prostate, and colon cancer. However, the exact relationship between IGF-1 and cancer is complex and not fully understood. High levels of IGF-1 may also be linked to an increased risk of cardiovascular diseases, including hypertension and atherosclerosis.

Most importantly, however, is the fact that abnormal IGF-1 levels can affect insulin sensitivity and glucose metabolism, potentially contributing to conditions like insulin resistance and type 2 diabetes. It is thought that changes in IGF-1 signaling may account for much of the insulin resistance associated with increases in GH levels. Research indicates that Sermorelin, however, doesn’t necessarily increase IGF-1 levels just because it increases GH levels. In at least one study, it was observed that IGF-1 levels did not significantly increase at 2 or 6 weeks of nightly treatment with Sermorelin but did increase with twice-daily administration. This suggests that the timing and overall quantity of Sermorelin can be used to control the peptide’s effects on IGF-1, with a higher frequency of administration resulting in more significant IGF-1 increases. This may be one of the reasons that Sermorelin has been associated with very few off-target effects and a host of beneficial effects.[7]

The same research has not been performed for Tesamorelin and, given that dosing and timing of administration appear to play an important role in how GHRH analogues affect IGF-1 levels, it is impossible to generalize the results of Sermorelin testing to Tesamorelin. Additional research in this area would be exceptionally useful as the ability to increase GH levels without increasing IGF-1 levels is of tremendous benefit.

Tesamorelin vs Sermorelin | Aging

Many age management practitioners consider growth hormone replacement therapy (GHRT) with human growth hormone to be among the most effective strategies for combating the signs of somatic aging currently in use. As noted above, however, direct GH supplementation comes with a number of serious side effects that limit its use.

A significant challenge arises with the practice of administering GH through subcutaneous bolus injections, resulting in a problematic "square wave" or pharmacological delivery pattern. This approach lacks the ability to mimic the natural feedback mechanisms that regulate hormone levels, leading to persistent tissue exposure to elevated concentrations, which can eventually result in tachyphylaxis, reduced effectiveness, or off-target effects. Importantly, the body cannot naturally adjust tissue exposure to direct GH supplementation, meaning those using GH must rely primarily on serum measurements of insulin-like growth factor-1 (IGF-1) and subjective signs/observations to estimate and adjust the dosage. All of these problems have led scientists to seek a better, more natural alternative to GH supplementation.

As noted above, Sermorelin does not appear to increase IGF-1 levels if administered properly[7], [8]. This is not the only benefit that Sermorelin has. Because Sermorelin increases endogenous GH indirectly, by stimulating the pituitary gland, it has certain physiological and clinical advantages over direct GH supplementation that include:

• The magnitude of effects is regulated by negative feedback involving the inhibitory neurohormone, somatostatin, making overdoses difficult if not impossible to achieve.
• The interaction of Sermorelin and somatostatin means the release of GH is episodic or intermittent rather than constant, resulting in a physiologic pattern of GH release.
• Sermorelin stimulates pituitary gene transcription of GH messenger RNA, increasing pituitary reserve and thereby preserving more of the growth hormone neuroendocrine axis, which is the first to fail during aging.
• Sermorelin helps to slow hypophyseal hormone decline by encouraging cellular division and differentiation in the pituitary gland.

All of these benefits, and more, have led some scientists to praise Sermorelin as the most effective age management compound yet developed. These are not the only anti-aging benefits that the peptide possesses either. Sermorelin is also a potent immune stimulator and has been linked to beneficial effects in the heart, brain, peripheral nervous system, and more.

It is likely that Tesamorelin has many of the same anti-aging benefits as Sermorelin, but they simply have not been tested as of yet. Until that happens, the question of Tesamorelin vs. Sermorelin in the realm of anti-aging properties is settled by saying that all of the available research supports Sermorelin in this capacity. Additional animal trials pitting these two peptides against one another in controlled conditions will be necessary to tease out the differences and determine which, if either, of these GHRH analogues provides the most benefit.

Tesamorelin vs Sermorelin | Heart Health

Heart disease is the leading cause of morbidity and mortality in most nations. Whether you think it is a consequence of diet or simply an artifact of our longer lifespans, treating heart disease effectively has been the subject of tens of billions of dollars of research. Scientists have spent the better part of the last century looking for ways to cure or prevent heart disease. There has been a lot of success on the treatment side of the equation, with new and increasingly innovative interventions making it possible to stop a heart attack in its tracks, effectively manage heart disease, or even replace the heart entirely. The holy grail, however, is prevention and though some progress has been made on that front, true success remains just out of grasp.

Several research studies have suggested that Sermorelin may offer potential benefits in mitigating cardiac scarring and remodeling that often occurs following a heart attack[9], [10]. This potential is rooted in the hypothesis that Sermorelin could enhance the survival of heart muscle cells, known as cardiomyocytes, through mechanisms such as reducing inflammation and promoting blood vessel growth[11]. These effects hold promise for improving heart function and overall cardiovascular health.

Preserving ejection fraction, which quantifies the amount of blood ejected by the heart in each contraction, is critical for maintaining efficient cardiac function. While the long-term effects of Sermorelin supplementation on heart function are not yet fully explored, there is a reasonable assumption that optimizing growth hormone levels may have potential advantages in sustaining optimal heart function throughout one's life[12]. Research conducted on large-animal models of chronic kidney disease has demonstrated that Sermorelin and other GHRH analogues can uphold ejection fraction, even in the presence of heart failure.

Evidence suggests that Sermorelin's signaling pathways could offer a novel molecular target to counteract dysfunctional cardiomyocyte relaxation by modifying the phosphorylation of cardiac muscle fibers. In simpler terms, Sermorelin may directly enhance heart function by improving the effectiveness of the heart muscle itself. However, this isn't the only benefit attributed to the peptide. Researchers have long recognized that Sermorelin and select GHRH analogues can reduce cardiac scarring, or fibrosis, and help preserve healthy heart tissue.

The advantages of Sermorelin for the heart are not solely preventative; research in rats indicates that Sermorelin, and potentially other GHRH analogues, can reverse ventricular remodeling that occurs post-heart attack. Studies show that this isn't just a molecular change; administering Sermorelin after a heart attack results in improved functional recovery of the heart. Rats receiving the peptide exhibit superior hemodynamic profiles compared to untreated rats. Treated rats display reduced cardiac muscle damage and increased cell division in both heart muscle cells and supportive cells[10].

Despite Sermorelin’s obvious benefits, and they are extensive, preliminary research indicates that Tesamorelin may be even more beneficial in moving research toward its ultimate goal of prevention. It has long been known that people living with HIV face an elevated risk of developing cardiovascular disease (CVD) as a result of abnormal fat distribution in and around the heart. Preventing CVD in HIV-positive individuals is deemed a critical medical intervention for their long-term well-being and has thus been an area of heavy research investment.

It only makes sense that a therapeutic aimed at directly reducing abnormal fat deposits would have benefit in reducing the fat deposits that increase the risk of heart disease. Thus, scientists set out to see if there was any benefit to the heart from the administration of Tesamorelin. Several studies indicate that Tesamorelin can lower triglyceride levels, total cholesterol levels, and non-HDL-C levels in HIV-positive patients. Notably, a 15-20% reduction in visceral adipose tissue achieved through Tesamorelin corresponds to a significant 50 mg decrease in triglyceride levels[3], [6], [13].

Research indicates that Tesamorelin may play a unique role in enhancing adipose tissue (AT) function, actually making fat less dangerous to the heart, brain, and other organs. It is thought that enlarged adipocytes trigger a pro-inflammatory state leading to tissue hypoxia, mitochondrial depletion, immune cell activation, infiltration, and disturbances in lipid and glucose metabolism. Tesamorelin appears to mitigate or even eliminate this state of dysfunction by restoring fat tissue to its more normal mode of operation[14], [15]. Thus, Tesamorelin has two very clear benefits in creating an environment that will help to prevent the development of heart disease.

Once again, it is difficult to draw a line separating Tesamorelin vs. Sermorelin in the realm of heart disease. After all, the peptides are quite similar and therefore could share many if not most of the same properties. Still, until the research is done, drawing too many inferences could be dangerous. As of this writing, most of the research into Sermorelin and heart disease has focused on the intervention side of the equation while most of the work on Tesamorelin and heart disease has focused on the preventative side of the equation. Thus, the benefit in heart disease goes to Tesamorelin, at least marginally, for its demonstrated ability to mitigate the kind of early changes that set up an internal environment that makes the body prone to heart disease. In other words, for preventative use, there is more research directly backing Tesamorelin vs. Sermorelin.

Tesamorelin vs Sermorelin | Heart Health

In the end, the debate between Tesamorelin vs. Sermorelin pits two very similar and highly effective peptides against each other in an artificial comparison. Research is expensive and time-consuming, and much of the research needed to draw conclusions about superiority has simply not been conducted. Furthermore, it may never be done. Given the similarity between these two peptides and the cost of conducting such research, the cost-benefit calculation suggests that it would be a waste of money to compare these peptides in most regards. Generally, what applies to one peptide is likely to apply to the other. As a result, scientists are more likely to monitor the use of these peptides in other capacities and then look for differences or similarities in the statistical data. This is a more cost-effective approach, but it will likely take some time before we have answers to many of the subtler questions. Until then, the debate between Tesamorelin vs. Sermorelin will continue, and people will continue to wonder which is superior. The best that can be done until the evidence is in is to use the available data to make educated decisions and then monitor the results.

Resources